angiotensin-converting enzyme

angiotensin-converting enzyme Angiotensin-converting enzyme (ACE) is a zinc-dependent peptidyl dipeptidase that plays a central role in peptide hormone metabolism and cardiovascular homeostasis. Initially characterized in biochemical studies from mid-20th century laboratories, ACE has been investigated across clinical cardiology, nephrology, and pharmacology research programs at institutions such as Harvard University, Johns Hopkins University, Mayo Clinic, Imperial College London, and Karolinska Institutet. ACE is a therapeutic target whose inhibition underpins major drug classes developed by pharmaceutical companies including Merck & Co., Pfizer, and Novartis and has influenced guidelines from organizations like the American Heart Association, the European Society of Cardiology, and the World Health Organization.

Structure and Biochemistry

ACE is a metallopeptidase belonging to the M13 family of zinc proteases, featuring a catalytic motif that coordinates a zinc ion via histidine residues conserved across species studied in laboratories at Max Planck Society and Cold Spring Harbor Laboratory. Crystallographic data from structural biology groups at University of California, San Francisco and University of Oxford reveal two homologous catalytic domains in the somatic isoform, each with a HEXXH zinc-binding sequence, resembling domain architecture reported for related enzymes in reports from Stanford University and Massachusetts Institute of Technology. The enzyme catalyzes conversion of angiotensin I to angiotensin II and degrades bradykinin through peptide bond hydrolysis, a reaction characterized by enzymologists at University of Tokyo and École Normale Supérieure using substrates defined in protocols influenced by methods from Max Planck Institute for Biophysical Chemistry. Post-translational modifications including N-linked glycosylation have been mapped by proteomics teams at Scripps Research, ETH Zurich, and University of Cambridge and show conservation patterns discussed in reviews associated with National Institutes of Health research consortia. Comparative structural analyses reference proteins studied at University College London and Duke University Medical Center.

Physiological Function and Regulation

ACE operates within the renin–angiotensin–aldosterone system studied by investigators at Cleveland Clinic, Beth Israel Deaconess Medical Center, and the National Heart, Lung, and Blood Institute; it increases vascular tone via production of angiotensin II and modulates inflammatory responses by degrading vasoactive peptides, phenomena examined in clinical trials sponsored by NHS England and research programs at University of Pennsylvania. Regulation occurs via transcriptional control influenced by signaling pathways characterized in research from Yale University, University of Chicago, and Columbia University, and by shedding of the ectodomain mediated by metalloproteinases investigated at Harvard Medical School and University of California, San Diego. Circulating and tissue-specific activities have been quantified in cohort studies involving centers like Mount Sinai Hospital, Karolinska University Hospital, and Seoul National University Hospital, informing population-level analyses by the Centers for Disease Control and Prevention and the European Centre for Disease Prevention and Control.

Genetics and Isoforms

The ACE gene was cloned in molecular biology programs at University of Cambridge and Imperial College London, with the insertion/deletion (I/D) polymorphism extensively genotyped in large consortia including studies coordinated by Framingham Heart Study, UK Biobank, and international projects supported by the Wellcome Trust. Somatic and testis-specific isoforms arise from alternative promoters; this isoform diversity was elucidated in genomic investigations at Cold Spring Harbor Laboratory and Broad Institute. Population genetics analyses across cohorts in China, India, Brazil, South Africa, and Sweden have reported allele frequency distributions referenced in meta-analyses curated by teams at McMaster University and University of Melbourne. Clinical genetics centers such as Great Ormond Street Hospital and St. Jude Children's Research Hospital have documented rare mutations that alter catalytic domains, complementing functional studies from University of Toronto.

Role in Disease and Pathophysiology

ACE activity is implicated in hypertension, heart failure, diabetic nephropathy, and stroke; these associations have been detailed in randomized trials conducted by networks including NIH Clinical Center, European Medicines Agency, and cooperative groups such as International Society of Hypertension. Pathophysiological mechanisms linking ACE to vascular remodeling, fibrosis, and inflammatory signaling have been modeled in animal studies from laboratories at Princeton University, University of California, Berkeley, and ETH Zurich. Elevated or reduced ACE expression correlates with outcomes in cohorts monitored by Johns Hopkins Hospital, Royal Brompton Hospital, and Singapore General Hospital. ACE interactions with pathways involving aldosterone and natriuretic peptides have been characterized in translational research at Vanderbilt University Medical Center and University of Freiburg, while effects on pulmonary pathology prompted investigations at National University of Singapore and during public health responses coordinated by World Health Organization.

Clinical Significance and Therapeutics

ACE inhibitors constitute a cornerstone of therapy for hypertension and heart failure, developed through drug discovery programs at Merck & Co., Ciba-Geigy (now part of Novartis), and Bayer AG and evaluated in landmark trials such as those led by CONSENSUS, SOLVD, and HOPE study groups. Clinical practice guidelines from the American College of Cardiology, European Society of Cardiology, and National Institute for Health and Care Excellence recommend ACE inhibitors for multiple indications; comparative effectiveness research has been published in journals affiliated with New England Journal of Medicine and The Lancet editorial offices. Adverse effects, including cough and angioedema, prompted mechanistic studies at Mayo Clinic and pharmacovigilance by agencies like the U.S. Food and Drug Administration and European Medicines Agency. Alternatives and adjuncts—angiotensin receptor blockers, neprilysin inhibitors, and direct renin inhibitors—were developed in parallel by companies including Novartis, AstraZeneca, and Takeda Pharmaceutical Company and assessed in multicenter trials coordinated with institutions such as Brigham and Women's Hospital and Johns Hopkins University School of Medicine.

Category:Enzymes